Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509481 · ClinicalTrials.gov registry record · Phase 2
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
A Phase 2 study, sponsored by Colorado State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,712
- Enrollment target
NCT02509481: Completed Phase 2 study, sponsored by Colorado State University.
NCT02509481 is a Phase 2 study that has completed, run by Colorado State University. The registered enrollment target is 2,712 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1939% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02509481, a Phase 2 study, has completed, sponsored by Colorado State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,712 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in reducing local malaria transmission and thus clinical malaria episodes in treated village children.
Primary Outcome
Cumulative incidence of malaria episodes in a cohort of village children ≤ 5 years of age (as assessed by active case surveillance in study villages - malaria episode defined as ≥38.0°C fever or history of fever in the last 24 hours + positive rapid diagnostic test for Plasmodium falciparum). Incidence is reported as malaria episodes per child over the course of the trial, a higher incidence is a worse outcome.
Interventions
- DRUG Ivermectin
- DRUG Albendazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,712 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT02509481 record still lists
NCT02509481 is an interventional study that assigns participants to a tested intervention. Its 2,712 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1939% higher).
The record links to 0 conditions, and to 2 interventions - of which Ivermectin is the first listed.
NCT02509481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02509481 about?
NCT02509481 is a clinical study titled "Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study". The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in reducing local malaria transmission and thus clinical malaria episodes in...
What is the current status of trial NCT02509481?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,712 participants. The study started on 2015-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02509481?
The interventions under investigation include: Ivermectin (DRUG), Albendazole (DRUG).
Who is sponsoring clinical trial NCT02509481?
This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02509481's enrollment target sits among peer trials
2,712 7th of 2000 higher than 1,994 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06085833 · 2,706 participants · NA
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia